Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057736 | 0.97 | PRCP (0.49) | PRCPCASP3ACEACE2MDM4 | |
| SCHEMBL31164831 | 0.90 | ACE (0.54) | ACEACE2LTA4H | |
| SCHEMBL31164828 | 0.90 | ACE (0.54) | ACEACE2LTA4H | |
| SCHEMBL30849154 | 0.89 | ACE (0.47) | PRCPCASP3ACEACE2MDM4 | |
| SCHEMBL24579222 | 0.87 | ACE (0.58) | ACEACE2LTA4H | |
| SCHEMBL29613906 | 0.87 | ACE (0.58) | ACEACE2LTA4H | |
| SCHEMBL29696658 | 0.87 | ACE (0.58) | ACEACE2LTA4H | |
| SCHEMBL29697676 | 0.87 | ACE (0.58) | ACEACE2LTA4H | |
| SCHEMBL24580400 | 0.86 | PRCP (0.52) | PRCPACEACE2MDM4TP53 | |
| SCHEMBL29583278 | 0.86 | ACE (0.51) | PRCPACEACE2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772227-A | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-10-15 | — | — | CN | disclosed |
| CN-110799520-B | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PRCP 90/4885CASP3 343/4885ACE 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.